Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies

Model estimates of potential benefits and harms

Roman Gulati, John L. Gore, Ruth Etzioni

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Background: The U.S. Preventive Services Task Force recently concluded that the harms of existing prostate-specific antigen (PSA) screening strategies outweigh the benefits. Objective: To evaluate comparative effectiveness of alternative PSA screening strategies. Design: Microsimulation model of prostate cancer incidence and mortality quantifying harms and lives saved for alternative PSA screening strategies. Data Sources: National and trial data on PSA growth, screening and biopsy patterns, incidence, treatment distributions, treatment efficacy, and mortality. Target Population: A contemporary cohort of U.S. men. Time Horizon: Lifetime. Perspective: Societal. Intervention: 35 screening strategies that vary by start and stop ages, screening intervals, and thresholds for biopsy referral. Outcome Measures: PSA tests, false-positive test results, cancer detected, overdiagnoses, prostate cancer deaths, lives saved, and months of life saved. Results of Base-Case Analysis: Without screening, the risk for prostate cancer death is 2.86%. A reference strategy that screens men aged 50 to 74 years annually with a PSA threshold for biopsy referral of 4 μg/L reduces the risk for prostate cancer death to 2.15%, with risk for overdiagnosis of 3.3%. A strategy that uses higher PSA thresholds for biopsy referral in older men achieves a similar risk for prostate cancer death (2.23%) but reduces the risk for overdiagnosis to 2.3%. A strategy that screens biennially with longer screening intervals for men with low PSA levels achieves similar risks for prostate cancer death (2.27%) and overdiagnosis (2.4%), but reduces total tests by 59% and false-positive results by 50%. Results of Sensitivity Analysis: Varying incidence inputs or reducing the survival improvement due to screening did not change conclusions. Limitation: The model is a simplification of the natural history of prostate cancer, and improvement in survival due to screening is uncertain. Conclusion: Compared with standard screening, PSA screening strategies that use higher thresholds for biopsy referral for older men and that screen men with low PSA levels less frequently can reduce harms while preserving lives. Primary Funding Source: National Cancer Institute and Centers for Disease Control and Prevention.

Original languageEnglish (US)
Pages (from-to)145-153
Number of pages9
JournalAnnals of internal medicine
Volume158
Issue number3
DOIs
StatePublished - Feb 5 2013
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Early Detection of Cancer
Prostatic Neoplasms
Biopsy
Referral and Consultation
Incidence
Survival
National Cancer Institute (U.S.)
Mortality
Health Services Needs and Demand
Information Storage and Retrieval
Advisory Committees
Centers for Disease Control and Prevention (U.S.)
Outcome Assessment (Health Care)
Medical Overuse

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies : Model estimates of potential benefits and harms. / Gulati, Roman; Gore, John L.; Etzioni, Ruth.

In: Annals of internal medicine, Vol. 158, No. 3, 05.02.2013, p. 145-153.

Research output: Contribution to journalArticle

@article{4a2f4e1741b9404f96d15ed23df9ff66,
title = "Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: Model estimates of potential benefits and harms",
abstract = "Background: The U.S. Preventive Services Task Force recently concluded that the harms of existing prostate-specific antigen (PSA) screening strategies outweigh the benefits. Objective: To evaluate comparative effectiveness of alternative PSA screening strategies. Design: Microsimulation model of prostate cancer incidence and mortality quantifying harms and lives saved for alternative PSA screening strategies. Data Sources: National and trial data on PSA growth, screening and biopsy patterns, incidence, treatment distributions, treatment efficacy, and mortality. Target Population: A contemporary cohort of U.S. men. Time Horizon: Lifetime. Perspective: Societal. Intervention: 35 screening strategies that vary by start and stop ages, screening intervals, and thresholds for biopsy referral. Outcome Measures: PSA tests, false-positive test results, cancer detected, overdiagnoses, prostate cancer deaths, lives saved, and months of life saved. Results of Base-Case Analysis: Without screening, the risk for prostate cancer death is 2.86{\%}. A reference strategy that screens men aged 50 to 74 years annually with a PSA threshold for biopsy referral of 4 μg/L reduces the risk for prostate cancer death to 2.15{\%}, with risk for overdiagnosis of 3.3{\%}. A strategy that uses higher PSA thresholds for biopsy referral in older men achieves a similar risk for prostate cancer death (2.23{\%}) but reduces the risk for overdiagnosis to 2.3{\%}. A strategy that screens biennially with longer screening intervals for men with low PSA levels achieves similar risks for prostate cancer death (2.27{\%}) and overdiagnosis (2.4{\%}), but reduces total tests by 59{\%} and false-positive results by 50{\%}. Results of Sensitivity Analysis: Varying incidence inputs or reducing the survival improvement due to screening did not change conclusions. Limitation: The model is a simplification of the natural history of prostate cancer, and improvement in survival due to screening is uncertain. Conclusion: Compared with standard screening, PSA screening strategies that use higher thresholds for biopsy referral for older men and that screen men with low PSA levels less frequently can reduce harms while preserving lives. Primary Funding Source: National Cancer Institute and Centers for Disease Control and Prevention.",
author = "Roman Gulati and Gore, {John L.} and Ruth Etzioni",
year = "2013",
month = "2",
day = "5",
doi = "10.7326/0003-4819-158-3-201302050-00003",
language = "English (US)",
volume = "158",
pages = "145--153",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "3",

}

TY - JOUR

T1 - Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies

T2 - Model estimates of potential benefits and harms

AU - Gulati, Roman

AU - Gore, John L.

AU - Etzioni, Ruth

PY - 2013/2/5

Y1 - 2013/2/5

N2 - Background: The U.S. Preventive Services Task Force recently concluded that the harms of existing prostate-specific antigen (PSA) screening strategies outweigh the benefits. Objective: To evaluate comparative effectiveness of alternative PSA screening strategies. Design: Microsimulation model of prostate cancer incidence and mortality quantifying harms and lives saved for alternative PSA screening strategies. Data Sources: National and trial data on PSA growth, screening and biopsy patterns, incidence, treatment distributions, treatment efficacy, and mortality. Target Population: A contemporary cohort of U.S. men. Time Horizon: Lifetime. Perspective: Societal. Intervention: 35 screening strategies that vary by start and stop ages, screening intervals, and thresholds for biopsy referral. Outcome Measures: PSA tests, false-positive test results, cancer detected, overdiagnoses, prostate cancer deaths, lives saved, and months of life saved. Results of Base-Case Analysis: Without screening, the risk for prostate cancer death is 2.86%. A reference strategy that screens men aged 50 to 74 years annually with a PSA threshold for biopsy referral of 4 μg/L reduces the risk for prostate cancer death to 2.15%, with risk for overdiagnosis of 3.3%. A strategy that uses higher PSA thresholds for biopsy referral in older men achieves a similar risk for prostate cancer death (2.23%) but reduces the risk for overdiagnosis to 2.3%. A strategy that screens biennially with longer screening intervals for men with low PSA levels achieves similar risks for prostate cancer death (2.27%) and overdiagnosis (2.4%), but reduces total tests by 59% and false-positive results by 50%. Results of Sensitivity Analysis: Varying incidence inputs or reducing the survival improvement due to screening did not change conclusions. Limitation: The model is a simplification of the natural history of prostate cancer, and improvement in survival due to screening is uncertain. Conclusion: Compared with standard screening, PSA screening strategies that use higher thresholds for biopsy referral for older men and that screen men with low PSA levels less frequently can reduce harms while preserving lives. Primary Funding Source: National Cancer Institute and Centers for Disease Control and Prevention.

AB - Background: The U.S. Preventive Services Task Force recently concluded that the harms of existing prostate-specific antigen (PSA) screening strategies outweigh the benefits. Objective: To evaluate comparative effectiveness of alternative PSA screening strategies. Design: Microsimulation model of prostate cancer incidence and mortality quantifying harms and lives saved for alternative PSA screening strategies. Data Sources: National and trial data on PSA growth, screening and biopsy patterns, incidence, treatment distributions, treatment efficacy, and mortality. Target Population: A contemporary cohort of U.S. men. Time Horizon: Lifetime. Perspective: Societal. Intervention: 35 screening strategies that vary by start and stop ages, screening intervals, and thresholds for biopsy referral. Outcome Measures: PSA tests, false-positive test results, cancer detected, overdiagnoses, prostate cancer deaths, lives saved, and months of life saved. Results of Base-Case Analysis: Without screening, the risk for prostate cancer death is 2.86%. A reference strategy that screens men aged 50 to 74 years annually with a PSA threshold for biopsy referral of 4 μg/L reduces the risk for prostate cancer death to 2.15%, with risk for overdiagnosis of 3.3%. A strategy that uses higher PSA thresholds for biopsy referral in older men achieves a similar risk for prostate cancer death (2.23%) but reduces the risk for overdiagnosis to 2.3%. A strategy that screens biennially with longer screening intervals for men with low PSA levels achieves similar risks for prostate cancer death (2.27%) and overdiagnosis (2.4%), but reduces total tests by 59% and false-positive results by 50%. Results of Sensitivity Analysis: Varying incidence inputs or reducing the survival improvement due to screening did not change conclusions. Limitation: The model is a simplification of the natural history of prostate cancer, and improvement in survival due to screening is uncertain. Conclusion: Compared with standard screening, PSA screening strategies that use higher thresholds for biopsy referral for older men and that screen men with low PSA levels less frequently can reduce harms while preserving lives. Primary Funding Source: National Cancer Institute and Centers for Disease Control and Prevention.

UR - http://www.scopus.com/inward/record.url?scp=84873364644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873364644&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-158-3-201302050-00003

DO - 10.7326/0003-4819-158-3-201302050-00003

M3 - Article

VL - 158

SP - 145

EP - 153

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -